LSMO 2019 Slides Day 1

LSMO 2019 Slides Day 1

Therapeutic approaches of metastatic hormone-dependent breast cancer

2- Adjuvant Endocrine Therapy in Breast Cancer

Advances in the management of ALKROS-1 NSCLC

CDK 4/6 Inhibitors as 1st Line Therapy in ER+HER2- MBC

Checkpoints inhibitors (CPIs) in the early setting of solid cancers Promising findings and perspectives

Beyond HER2 and CDK4/6 agents in advanced breast cancers

Genomic Expression Profiling and Selection of Adjuvant

Neoadjuvant Treatment in Primary Operable Breast Cancer

CDK4/6 inhibitors Changing Practice toward a comprehensive management of HR+HER2- metastatic Breast Cancer

Immunotherapy in triple negative breast cancer

Treating the spectrum of neuroendocrine tumors sequential therapy

Comprehensive Care for Patients With Multiple Myeloma Bone Health Considerations

Current Questions on Why, When and How to Treat Non-Metastatic Castration-Resistant Prostate Cancer

Targeting Immune Checkpoints in Triple Negative Breast Cancer (TNBC)